Bent Frandsen
Vorstandsvorsitzender bei EXPRES2ION BIOTECH HOLDING AB
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Willem Adriaan de Jongh | M | - |
Adaptvac ApS
ExpreS2ion Biotechnologies ApS
 ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 15 Jahre |
| Charlotte Dyring | M | 56 |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 15 Jahre |
| Jakob Knudsen | M | 56 |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 7 Jahre |
| Martin Jensen | M | 64 |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 15 Jahre |
| Allan Rosetzsky | M | 76 |
Adaptvac ApS
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 14 Jahre |
| Gitte L. Pedersen | F | 61 |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | - |
| Keith Alexander | M | 48 | 4 Jahre | |
| Karin Garre | M | 67 | 3 Jahre | |
| Sara Sande | F | 49 | 3 Jahre | |
| Farshad Guirakhoo | M | 70 | 1 Jahre | |
| Max M. Søgaard | M | - | 11 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michael Rosenvold | M | 57 |
Copenhagen Business School
| 6 Jahre |
| Jørgen Drejer | M | 69 |
NsGene A/S
 NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 13 Jahre |
| Thomas Stig Plenborg | M | 57 |
Copenhagen Business School
| 4 Jahre |
| Steen Klysner | M | - | - | |
| Henrik Jeppesen | M | - |
Copenhagen Business School
| 5 Jahre |
| Jan Fredskilde Andersen | M | 57 |
Copenhagen Business School
| 6 Jahre |
| Per Toelstang | M | 58 |
Copenhagen Business School
| 7 Jahre |
| Mats Gunnar Pettersson | M | 78 |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 4 Jahre |
| Morten Hultberg Buchgreitz | M | 57 |
Copenhagen Business School
| 1 Jahre |
| Thomas Kirk Vilsbøll | M | 57 |
Copenhagen Business School
| 1 Jahre |
| Carsten Nielsen | M | - |
Copenhagen Business School
| 4 Jahre |
| Christian Poulsen | M | 58 |
Copenhagen Business School
| 4 Jahre |
| Stina Bjerg Nielsen | F | - |
Copenhagen Business School
| 4 Jahre |
| Søren Svendsen | M | 58 |
Copenhagen Business School
| 1 Jahre |
| Rene Spurré | M | - |
Copenhagen Business School
| 4 Jahre |
| Eske Rygaard-Hjalsted | M | - | 1 Jahre | |
| Henriette Fenger Ellekrog | F | 58 |
Copenhagen Business School
| 1 Jahre |
| Claus Due Pedersen | M | - |
Copenhagen Business School
| 4 Jahre |
| Siggi Saevarsson | M | - |
Copenhagen Business School
| 3 Jahre |
| Karsten Winther | M | 54 |
Copenhagen Business School
| 4 Jahre |
| Charlotte Blicher | F | - |
Copenhagen Business School
| 3 Jahre |
| Mette Thorn | M | - | 2 Jahre | |
| Eivind Hauglie-Hansen | M | - |
Copenhagen Business School
| 1 Jahre |
| Jesper Fors Holmark | M | 58 |
Copenhagen Business School
| 4 Jahre |
| Pernille Erenbjerg | F | 57 |
Copenhagen Business School
| 1 Jahre |
| Bent Moltved | M | - |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 12 Jahre |
| Jesper Brandgaard | M | 60 |
Copenhagen Business School
| 2 Jahre |
| Tonny Andersen | M | 59 |
Copenhagen Business School
| 4 Jahre |
| Annemette Nøhr | F | 61 |
Copenhagen Business School
| 1 Jahre |
| Thomas Videbaek | M | 63 |
Copenhagen Business School
| 4 Jahre |
| Jørgen Buus Lassen | M | 90 |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 9 Jahre |
| Jens Hesselberg Lund | M | 54 |
Copenhagen Business School
| 5 Jahre |
| Henrik Jeberg | M | - |
Copenhagen Business School
| 3 Jahre |
| Helle Bjerre | F | 57 |
Copenhagen Business School
| 4 Jahre |
| Rúni Hansen | M | 57 |
Copenhagen Business School
| 1 Jahre |
| Heidi Birgitte Nielsen | F | 60 |
Copenhagen Business School
| 4 Jahre |
| Philip Kusk | M | - |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 12 Jahre |
| Hans-Christian Olesen | M | 56 |
Copenhagen Business School
| 4 Jahre |
| Hans Peter Holst | M | 82 |
Copenhagen Business School
| 2 Jahre |
| Per Madsen | M | 56 |
Copenhagen Business School
| 1 Jahre |
| Bjarke Pålsson | M | 56 |
Copenhagen Business School
| 1 Jahre |
| Stein-Tore Nybrodahl | M | 59 |
Copenhagen Business School
| 1 Jahre |
| Mattis Ranthe | M | - | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Dänemark | 54 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Bent Frandsen
- Persönliches Netzwerk
